ACM
TVTX icon

ADAR1 Capital Management’s Travere Therapeutics TVTX Stock Holding History

ADAR1 Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-100
Closed -$771 – 314
2024
Q1 		$771 Hold
100
– – ﹤0.01% 253
2023
Q4 		$899 Buy
+100
New +$728 ﹤0.01% 160

Other funds holding TVTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

ADAR1 Capital Management's TVTX Position: Q2 2024 in Review

ADAR1 Capital Management sold out of Travere Therapeutics (TVTX) in Q2 2024, closing a stake of 100 shares — an estimated $771 sold.

ADAR1 Capital Management first reported a position in TVTX in Q4 2023 and held it in 2 quarters. The position peaked at $899 in Q4 2023. 173 funds tracked by Wall St. Rank hold TVTX as of Q2 2024.

  • ADAR1 Capital Management reported no remaining Travere Therapeutics position as of Q2 2024 after selling out during the quarter.
  • ADAR1 Capital Management sold 100 Travere Therapeutics shares in Q2 2024, an estimated $771.
  • ADAR1 Capital Management first reported a position in Travere Therapeutics in Q4 2023 and held it in 2 quarters.
  • ADAR1 Capital Management's Travere Therapeutics position peaked at $899 in Q4 2023.
  • 173 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2024.

Based on ADAR1 Capital Management's 13F filing for Q2 2024, filed 13 Aug 2024.